TG Therapeutics, Inc. (TGTX)

In the past six months, TG Therapeutics' stock has been impacted by financial results and guidance, including revenue reports for Q4 2025 and full year 2025, and 2026 financial guidance. The company secured an additional $500 million in non-dilutive capital from Blue Owl and expanded its share repurchase program to $300 million. The stock showed an upward trend, with analysts giving TG Therapeutics a consensus rating of "Moderate Buy" with an average rating score of 2.83.

The provided information does not explicitly state any demand seasonality for TG Therapeutics, Inc.'s products or services. The company's primary product, BRIUMVI, treats a chronic condition (multiple sclerosis), which typically suggests a more consistent demand rather than seasonal fluctuations.

TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on novel treatments for B-cell diseases, operating within the Biotechnology industry. Its flagship product is BRIUMVI (ublituximab-xiiy), a monoclonal antibody therapy approved for relapsing forms of multiple sclerosis (RMS). The company also has a pipeline of investigational medicines, including TG-1701, Azer-Cel, and TG-1801, all in Phase 1 trials for B-cell disorders. TG Therapeutics was previously associated with umbralisib (UKONIQ®), which received accelerated FDA approval for certain lymphomas.

TG Therapeutics generates most of its revenue from BRIUMVI sales in the United States. BRIUMVI has also received regulatory approvals in several international regions, including the European Union, the United Kingdom, Switzerland, and Australia. The company's headquarters are located in Morrisville, North Carolina, United States.

In the past year, TG Therapeutics has worked to enhance its brand reputation through initiatives related to multiple sclerosis awareness. The company launched "Next In MS™," a platform designed to foster open conversations about living with MS, including a collaboration with actress Christina Applegate to raise awareness of multiple sclerosis through a Super Bowl LX commercial. This aims to support people living with MS and their healthcare providers, positively impacting the company's reputation.

TG Therapeutics, Inc. has a significant number of institutional owners and shareholders, with 358 institutional owners holding a total of 103,307,269 shares. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, and State Street Corp. Michael S. Weiss, the company's Chairman and Chief Executive Officer, is the largest individual shareholder, owning 33,760,975 shares, representing 21.14% of the company. Institutional shareholders own 64.59% of the company, while insiders own 46.63%.